{"gene":"CNR2","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1997,"finding":"CB2 (CNR2) is a G protein-coupled receptor that couples to Gi proteins; its effector systems include inhibition of adenylyl cyclase. CB2 receptors are present in peripheral tissues and immune system.","method":"Pharmacological characterization, radioligand binding, effector assays","journal":"Pharmacology & therapeutics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — foundational pharmacological characterization replicated across multiple labs over decades","pmids":["9336020"],"is_preprint":false},{"year":1998,"finding":"CB2 receptor expression is downregulated during B-cell differentiation (lowest in germinal center centroblasts), and CB2 receptor activation by cannabinoid agonist CP55,940 enhanced CD40-mediated B-cell proliferation, an effect blocked by CB2 antagonist SR 144528 but not CB1 antagonist SR 141716, demonstrating functional CB2 signaling in B-cell differentiation.","method":"Immunopurified anti-CB2 antibodies, dual-color confocal microscopy, flow cytometry, proliferation assays with selective antagonists","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (immunostaining, mRNA, protein, functional assay with receptor-selective pharmacology)","pmids":["9808554"],"is_preprint":false},{"year":2002,"finding":"Rat CB2 (rCB2) activates mitogen-activated protein kinase (MAPK/ERK) when stably expressed in CHO cells, establishing a direct signaling output of CB2 receptor activation.","method":"Stable expression in CHO cells, MAPK activation assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, single method (MAPK assay in heterologous expression system)","pmids":["12084572"],"is_preprint":false},{"year":2002,"finding":"Functional, epitope-tagged CB2 receptor was expressed in Pichia pastoris with pharmacological binding profile similar to mammalian-expressed receptor, and purified receptor was characterized by MALDI/TOF and ESI mass spectrometry.","method":"Heterologous expression in P. pastoris, radioligand binding, metal chelating chromatography, MALDI/TOF and ESI mass spectrometry","journal":"Protein expression and purification","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — successful purification and functional validation but single lab, expression system study","pmids":["12460775"],"is_preprint":false},{"year":2006,"finding":"CB2-deficient mice show accelerated age-related trabecular bone loss with increased osteoclast numbers and decreased osteoblast precursors; CB2 is expressed in osteoblasts, osteocytes, and osteoclasts. A CB2-specific agonist enhances osteoblast number/activity and restrains osteoclastogenesis by inhibiting osteoclast precursor proliferation and RANKL expression in bone marrow-derived osteoblasts/stromal cells, and attenuates ovariectomy-induced bone loss.","method":"CB2 knockout mice, histomorphometry, pharmacological agonist treatment, ovariectomy model, bone cell culture assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout plus pharmacological rescue with multiple orthogonal readouts across multiple models","pmids":["16407142"],"is_preprint":false},{"year":2006,"finding":"CB2 receptor activation by AM1241 produces antinociception in wild-type mice but has no effect in CB2 knockout mice, demonstrating that antinociceptive effects of AM1241 are mediated specifically through CB2 receptors in vivo.","method":"CB2 knockout mice vs. wild-type, thermal nociception assay, pharmacological challenge","journal":"Pain","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with pharmacological validation, replicated with multiple agonists","pmids":["16563625"],"is_preprint":false},{"year":2007,"finding":"CB2 receptor activation in neural stem/precursor cells (neurospheres) stimulates proliferation via a phosphoinositide-3 kinase (PI3K)/Akt signaling pathway; selective CB2 agonist JWH-056 stimulates neurosphere formation, and CB2 antagonist SR-144528 blocks basal proliferation, indicating endogenous cannabinoid tone through CB2.","method":"Neurosphere cultures, BrdU incorporation, pharmacological agonists/antagonists, PI3K/Akt inhibitor (BML-257)","journal":"The European journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective pharmacology with PI3K/Akt pathway inhibitor, two orthogonal readouts (BrdU and neurosphere formation)","pmids":["17328768"],"is_preprint":false},{"year":2009,"finding":"CB2 receptor activation by selective agonist JWH133 induced ERK1/2 MAPK phosphorylation in spermatogonia and promoted their progression toward meiosis, increasing cells positive for meiotic marker SCP3 and early meiotic prophase gene expression; endogenous 2-AG (higher in mitotic germ cells) is the likely endocannabinoid signal acting through CB2 during spermatogenesis.","method":"Purified germ cell fractions, primary spermatogonia cultures, selective CB2 agonist, Western blot (ERK phosphorylation), immunostaining for SCP3, RT-PCR for meiotic genes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods in primary cells with specific pharmacological tools and functional meiosis readout","pmids":["19541620"],"is_preprint":false},{"year":2009,"finding":"CB2 limits leukocyte infiltration and tissue fibrosis in experimental dermal fibrosis; the fibrosis-suppressing effect is mediated by leukocyte-expressed CB2, as shown by bone marrow transplantation: CB2-/- bone marrow transplanted into wild-type mice recapitulated increased fibrosis, while wild-type marrow into CB2-/- mice rescued the phenotype.","method":"CB2 knockout mice, bleomycin-induced fibrosis model, pharmacological agonist/antagonist treatment, bone marrow transplantation, histology","journal":"Arthritis and rheumatism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout plus bone marrow transplantation epistasis plus pharmacological rescue, multiple orthogonal approaches","pmids":["19333940"],"is_preprint":false},{"year":2011,"finding":"CB2 receptor signals through a Gi protein-cyclin D1 mitogenic axis in osteoblasts: CB2 activation stimulates ERK1/2 phosphorylation, de novo synthesis of MAPKAPK2, CREB transcriptional activation, and cyclin D1 mRNA expression; these effects are blocked by pertussis toxin (Gi inhibitor), MEK-ERK1/2 inhibitors, and Mapkapk2 siRNA.","method":"Osteoblast cultures (MC3T3 E1 and primary calvarial), selective CB2 agonists, Western blot, RT-PCR, CREB reporter assay, Mapkapk2 siRNA knockdown, pertussis toxin treatment","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including siRNA knockdown, pharmacological inhibitors at multiple pathway nodes, and Gi pathway confirmation with pertussis toxin","pmids":["20803555"],"is_preprint":false},{"year":2012,"finding":"CB2 and CB1 receptors form functional heteromers in transfected neuronal cells and in rat brain (pineal gland, nucleus accumbens, globus pallidus). Within CB1-CB2 heteromers, co-activation produces negative cross-talk in Akt phosphorylation and neurite outgrowth. CB1 antagonists block CB2 agonist effects and vice versa (bidirectional cross-antagonism), a property unique to the heteromeric complex.","method":"BRET, FRET, co-immunoprecipitation in transfected cells and rat brain tissue, Akt phosphorylation assay, neurite outgrowth assay, pharmacological cross-antagonism","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — biophysical (BRET/FRET) plus biochemical (Co-IP) plus functional assays in both heterologous system and native brain tissue","pmids":["22532560"],"is_preprint":false},{"year":2013,"finding":"CB2 receptor activation by trans-caryophyllene (TC) reduced ischemic neuronal injury through AMPK/CREB signaling: TC enhanced phosphorylation of AMPK and CREB and increased BDNF expression; selective AMPK and CREB inhibitors abolished TC neuroprotection. TC failed to alter Akt or ERK activity (two canonical CB2R pathways). Effects were reversed by CB2 antagonist AM630 but not CB1 antagonist AM251.","method":"Rat cortical neuron/glia OGD/R model, CB2 knockout validation with AM630/AM251, Western blot, selective kinase inhibitors, in vivo rat ischemia model","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple pathway inhibitors, receptor-selective pharmacology, in vitro and in vivo models, orthogonal biochemical readouts","pmids":["23414569"],"is_preprint":false},{"year":2013,"finding":"CB2 receptor activation by selective agonist O-1966 decreased nuclear NF-κB and NFAT levels in wild-type T-cells but not in CB2 knockout T-cells, and increased IL-10 production and regulatory T-cell (Treg) percentage in mixed lymphocyte reactions; increased IL-10 partially mediated the immunosuppressive effects.","method":"CB2 knockout mouse T-cells, mixed lymphocyte reaction, nuclear transcription factor assays, PCR T-cell activation array, IL-10 ELISA, anti-IL-10 neutralization","journal":"Journal of neuroimmune pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout controls plus multiple pathway readouts (NF-κB, NFAT, IL-10, Tregs) and neutralization experiment","pmids":["25980325"],"is_preprint":false},{"year":2013,"finding":"CB2 receptor modulates axon guidance in the retino-thalamic pathway in a PKA-dependent manner requiring the netrin-1 receptor DCC (Deleted in Colorectal Cancer); CB2R activation induced growth cone morphological changes, and cnr2-/- mice showed abnormal eye-specific segregation of retinal projections in the dLGN.","method":"cnr2 knockout mice, in vitro axon guidance assays, PKA inhibitor experiments, in vivo retino-thalamic tracing","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with specific phenotypic readout plus pharmacological PKA pathway dissection and in vivo circuit analysis","pmids":["23951024"],"is_preprint":false},{"year":2014,"finding":"GPR55 and CB2 receptors form heteromers in HEK293 cells (confirmed by co-immunoprecipitation and BRET); heteromerization selectively modulates signaling: GPR55-mediated transcription factor activation (NFAT, NF-κB, CRE) was reduced, while ERK1/2-MAPK activation was potentiated in the presence of CB2; CB2 signaling was also modified by co-expression with GPR55.","method":"Co-immunoprecipitation, BRET, label-free assays (Epic DMR and CellKey impedance), ERK1/2 phosphorylation assay, gene reporter assays","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus BRET plus multiple functional readouts, orthogonal methods","pmids":["25048571"],"is_preprint":false},{"year":2014,"finding":"CB2 and GPR55 form heteromers in cancer cells with unique signaling properties; these heteromeric complexes modulate the antitumoral activity of cannabinoids in vivo.","method":"Co-immunoprecipitation, proximity ligation assay, signaling assays, in vivo tumor model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and PLA plus in vivo functional data, single lab","pmids":["24942731"],"is_preprint":false},{"year":2015,"finding":"HER2 upregulates CB2 expression by activating transcription factor ELK1 via the ERK cascade; increased CB2 expression activates HER2 pro-oncogenic signaling at the level of tyrosine kinase c-SRC; HER2 and CB2 form heteromers in cancer cells.","method":"siRNA/shRNA knockdown, overexpression plasmids, co-immunoprecipitation, proximity ligation assay, colocalization, MMTV-neu transgenic mice with CB2 knockout, biochemical signaling assays","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, PLA, genetic knockdown/KO, mouse model) demonstrating bidirectional HER2-CB2 interaction and signaling","pmids":["25855725"],"is_preprint":false},{"year":2016,"finding":"CB2 receptor ligands display strong and varied functional selectivity: classic cannabinoids (e.g., JWH133) are highly efficacious for Gi-mediated adenylyl cyclase inhibition but fail to recruit arrestins (G-protein biased); endocannabinoids are also G-protein biased; aminoalkylindoles (e.g., WIN55212-2, UR144) show arrestin recruitment with varying cyclase efficacy; SR144258 is inverse agonist at both pathways; AM630 and JTE907 are inverse agonists at cyclase but low-efficacy agonists for arrestin recruitment.","method":"Adenylyl cyclase inhibition assay, β-arrestin recruitment assay (BRET-based), diverse CB2 ligand panel","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic screen with two orthogonal assays across a large structurally diverse ligand panel","pmids":["27194477"],"is_preprint":false},{"year":2018,"finding":"CXCR4 and CB2 form heterodimers upon simultaneous agonist stimulation; this heterodimeric association inhibits CXCR4-mediated cell migration, invasion, and adhesion through inhibition of the Gα13/RhoA signaling axis, decreasing protein expression of Gα13 and RhoA, abrogating RhoA-mediated cytoskeletal rearrangement, and reducing integrin α5 (ITGA5) expression.","method":"Co-immunoprecipitation, confocal colocalization, migration/invasion/adhesion assays, Western blot for Gα13/RhoA, cytoskeletal rearrangement imaging","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus multiple functional readouts with pathway mechanistic dissection, single lab","pmids":["29330286"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of human CB2 receptor in complex with antagonist AM10257 was solved at 2.8 Å resolution. The structure revealed a distinctly different binding pose compared with CB1, but the extracellular portion shares conformational similarity with agonist-bound CB1. Mutagenesis and molecular docking identified molecular determinants of CB2/CB1 selectivity and the CB2 activation mechanism.","method":"X-ray crystallography (2.8 Å), site-directed mutagenesis, molecular docking, pharmacological assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis plus functional validation in one study","pmids":["30639103"],"is_preprint":false},{"year":2022,"finding":"CNR2 (CB2 receptor) binds to JAK1 in T cells and inhibits downstream STAT signaling; this was demonstrated using a knock-in mouse model expressing FLAG-tagged Cnr2, with cannabinoids (THC and AEA) impairing tumor-specific T-cell function through CNR2-mediated JAK1/STAT inhibition.","method":"FLAG-Cnr2 knock-in mouse model, co-immunoprecipitation (FLAG pulldown for JAK1 binding), T-cell functional assays, STAT phosphorylation assays, in vivo tumor models","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse model with tagged endogenous receptor plus Co-IP demonstrating JAK1 binding plus functional pathway readouts","pmids":["35383142"],"is_preprint":false},{"year":2022,"finding":"CB2 receptors localized to peripheral sensory neurons (advillin-expressing) are necessary for both CB2 agonist (AM1710 and LY2828360) antinociceptive efficacy and sparing of morphine tolerance in a mouse model of antiretroviral toxic neuropathy; advillinCre/+;CB2f/f conditional knockout mice lacked these CB2 agonist effects.","method":"Conditional knockout (advillinCre/+;CB2f/f), global CB2 KO, neuropathic pain behavioral assays, morphine tolerance assay, cytokine mRNA measurement","journal":"Pharmacological research","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockout with multiple behavioral and molecular readouts, two structurally distinct CB2 agonists tested","pmids":["36417942"],"is_preprint":false},{"year":2022,"finding":"CB2 receptor activation inhibits microglial phagocytic function through β-arrestin2/ERK1/2 and PI3K/AKT/GSK-3β signaling pathways leading to nuclear translocation of Nurr1; positive feedback exists between CB2 receptor and Nurr1 expression; ERK1/2 plays a more dominant role than AKT in the CB2-Nurr1 axis.","method":"BV-2 cells and primary microglia, CB2 agonists (JWH015, 2-AG), selective pathway inhibitors (U0126, LY294002), Nurr1 overexpression, nuclear fractionation Western blot, phagocytosis assay","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological pathway inhibitors and functional phagocytosis readout, single lab","pmids":["35132190"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of CB2 receptor bound to multiple agonists (LEI-102, APD371, HU308, CP55,940) identified key residues for CB2 activation by site-directed mutagenesis and binding kinetics; highly lipophilic agonists (HU308 and endocannabinoids) access the binding pocket through a membrane channel formed by TM1-TM7, while more polar agonists enter directly.","method":"Cryo-EM structural determination, site-directed mutagenesis, radioligand binding kinetics, molecular docking, in vivo pharmacology (oral efficacy in nephropathy model)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure plus mutagenesis plus binding kinetics plus in vivo validation, multiple ligands compared","pmids":["36922494"],"is_preprint":false},{"year":2024,"finding":"A homobivalent ligand simultaneously binding both protomers of the CB2 receptor homodimer (one pharmacophore at orthosteric site, one at a TM1-TM7 membrane-oriented pocket of partner protomer) modulates CB2R homodimerization dynamics, resulting in increased potency for Gi-mediated signaling and enhanced β-arrestin recruitment.","method":"Computational docking, BRET for homodimerization, Gi signaling assays, β-arrestin recruitment assays, bivalent ligand pharmacology","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BRET for dimerization plus functional assays, computational modeling supporting binding mode, single lab","pmids":["39179054"],"is_preprint":false}],"current_model":"CNR2/CB2 is a Gi/o protein-coupled receptor predominantly expressed in immune cells and peripheral tissues (with lower-level neuronal/glial expression), whose activation inhibits adenylyl cyclase, activates ERK1/2 MAPK through Gi, and can signal through AMPK/CREB and PI3K/Akt pathways depending on cell context; structurally, crystal and cryo-EM structures have defined its orthosteric binding pocket, a lipophilic TM1-TM7 membrane access channel for endocannabinoids, and the molecular basis of CB1/CB2 selectivity; CB2 forms functionally distinct heteromers with CB1, GPR55, HER2, and CXCR4 that alter downstream signaling; it directly binds JAK1 to suppress STAT signaling in T cells; functionally, CB2 regulates osteoblast/osteoclast activity via a Gi-cyclin D1 mitogenic axis, suppresses leukocyte infiltration and fibrosis, promotes neural stem cell proliferation, modulates axon guidance through PKA-DCC, inhibits microglial phagocytosis via β-arrestin2/ERK-Nurr1, and peripheral sensory neuron CB2 specifically mediates antinociception and morphine tolerance-sparing effects."},"narrative":{"mechanistic_narrative":"CNR2/CB2 is a Gi/o-coupled cannabinoid receptor that transduces endocannabinoid signals predominantly in immune and peripheral tissues, classically inhibiting adenylyl cyclase and activating ERK1/2 MAPK [PMID:9336020, PMID:12084572]. Through its Gi output CB2 drives a mitogenic axis in osteoblasts coupling ERK1/2, MAPKAPK2, and CREB to cyclin D1 transcription, and genetically governs bone homeostasis by promoting osteoblast activity while restraining osteoclastogenesis [PMID:16407142, PMID:20803555]. Depending on cell context CB2 signals through additional effector arms—PI3K/Akt to drive neural stem cell and germ cell proliferation [PMID:17328768, PMID:19541620], AMPK/CREB/BDNF for neuroprotection [PMID:23414569], and β-arrestin2/ERK-PI3K/AKT/GSK-3β converging on Nurr1 to suppress microglial phagocytosis [PMID:35132190]. CB2 ligands are strongly functionally selective, with classic cannabinoids and endocannabinoids biased toward G-protein signaling over arrestin recruitment [PMID:27194477]. In immune cells CB2 is broadly anti-inflammatory: it enhances CD40-driven B-cell proliferation [PMID:9808554], dampens NF-κB/NFAT and promotes IL-10/Treg responses in T cells [PMID:25980325], limits leukocyte-driven tissue fibrosis [PMID:19333940], and directly binds JAK1 to inhibit STAT signaling and suppress tumor-specific T-cell function [PMID:35383142]. CB2 forms functionally distinct heteromers with CB1, GPR55, HER2, and CXCR4 that reshape downstream signaling, including cross-antagonism with CB1, modulation of GPR55 transcription-factor output, HER2 pro-oncogenic feedback, and inhibition of CXCR4-driven migration via Gα13/RhoA [PMID:22532560, PMID:25048571, PMID:25855725, PMID:29330286]. In the nervous system CB2 also modulates axon guidance through a PKA-DCC mechanism [PMID:23951024], and peripheral sensory-neuron CB2 specifically mediates antinociception and morphine-tolerance sparing [PMID:16563625, PMID:36417942]. Crystal and cryo-EM structures define the CB2 orthosteric pocket, the molecular basis of CB1/CB2 selectivity, and a lipophilic TM1-TM7 membrane-access channel used by endocannabinoids [PMID:30639103, PMID:36922494].","teleology":[{"year":1997,"claim":"Established the foundational identity of CB2 as a Gi-coupled receptor with a peripheral/immune distribution and adenylyl cyclase inhibition as a core effector, defining the receptor's basic signaling logic.","evidence":"Pharmacological characterization, radioligand binding, and effector assays","pmids":["9336020"],"confidence":"High","gaps":["Did not define downstream kinase cascades","Did not resolve cell-type-specific functions"]},{"year":1998,"claim":"Demonstrated CB2 is functionally engaged in immune cell biology, showing receptor-selective enhancement of CD40-mediated B-cell proliferation during differentiation.","evidence":"Anti-CB2 immunostaining, flow cytometry, and proliferation assays with CB2- vs CB1-selective antagonists","pmids":["9808554"],"confidence":"High","gaps":["Signaling pathway linking CB2 to proliferation not defined","In vivo relevance to humoral immunity untested"]},{"year":2002,"claim":"Identified MAPK/ERK activation as a direct CB2 signaling output, extending the effector repertoire beyond cyclase inhibition.","evidence":"Stable rat CB2 expression in CHO cells with MAPK activation assay","pmids":["12084572"],"confidence":"Medium","gaps":["Single heterologous system","G-protein dependence not dissected"]},{"year":2006,"claim":"Genetic and pharmacological evidence placed CB2 at the center of bone homeostasis and in vivo antinociception, two of its defining physiological roles.","evidence":"CB2 knockout mice with histomorphometry, ovariectomy and bone cell models, and thermal nociception with CB2-selective agonist AM1241","pmids":["16407142","16563625"],"confidence":"High","gaps":["Intracellular mechanism in bone cells not yet resolved","Cell type mediating antinociception not localized"]},{"year":2007,"claim":"Linked CB2 to proliferative control in neural and germ-cell lineages, identifying PI3K/Akt and ERK1/2 as proliferative effector arms under endogenous endocannabinoid tone.","evidence":"Neurosphere cultures with PI3K/Akt inhibitor and selective pharmacology; primary spermatogonia with ERK phosphorylation and meiotic markers (2009)","pmids":["17328768","19541620"],"confidence":"Medium","gaps":["Reliance on pharmacology rather than genetic deletion in these systems","Endocannabinoid identity inferred"]},{"year":2009,"claim":"Bone marrow transplantation epistasis established that leukocyte-expressed CB2 is the cell-autonomous source restraining tissue fibrosis, distinguishing immune from parenchymal CB2.","evidence":"CB2 knockout, bleomycin fibrosis model, and reciprocal bone marrow transplantation","pmids":["19333940"],"confidence":"High","gaps":["Specific leukocyte subset not identified","Downstream anti-fibrotic mediators undefined"]},{"year":2011,"claim":"Resolved the CB2 mitogenic mechanism in osteoblasts as a Gi-ERK1/2-MAPKAPK2-CREB-cyclin D1 axis, providing a defined pathway for CB2-driven proliferation.","evidence":"Osteoblast cultures with pertussis toxin, MEK inhibitors, Mapkapk2 siRNA, and CREB reporter assays","pmids":["20803555"],"confidence":"High","gaps":["Generalizability of this axis to other proliferative tissues untested"]},{"year":2012,"claim":"Demonstrated that CB2 oligomerizes with other receptors to generate novel signaling units, beginning with CB1-CB2 heteromers showing bidirectional cross-antagonism and negative Akt cross-talk.","evidence":"BRET, FRET, Co-IP in transfected cells and rat brain with Akt and neurite outgrowth readouts","pmids":["22532560"],"confidence":"High","gaps":["Stoichiometry and structural interface unresolved","Physiological consequence in native circuits limited"]},{"year":2013,"claim":"Expanded CB2's context-dependent signaling and partner network: AMPK/CREB neuroprotection, T-cell immunosuppression via NF-κB/NFAT and IL-10/Tregs, GPR55 heteromer signaling rewiring, and PKA-DCC-dependent axon guidance.","evidence":"OGD/R neuron models, CB2-KO T cells in mixed lymphocyte reactions, Co-IP/BRET for GPR55 heteromers, and cnr2-KO retino-thalamic tracing","pmids":["23414569","25980325","25048571","23951024"],"confidence":"High","gaps":["Which effector arm dominates is cell-context specific and not unified","Heteromer interfaces not structurally defined"]},{"year":2015,"claim":"Established bidirectional HER2-CB2 cross-regulation in cancer, where HER2 induces CB2 via ERK-ELK1 and CB2 in turn amplifies HER2 oncogenic signaling through c-SRC.","evidence":"siRNA/shRNA, overexpression, Co-IP, PLA, and MMTV-neu;CB2-KO mouse model","pmids":["25855725"],"confidence":"High","gaps":["Heteromer structural basis undefined","Therapeutic exploitability untested"]},{"year":2016,"claim":"Systematically defined CB2 ligand functional selectivity, showing classic cannabinoids and endocannabinoids are G-protein biased while aminoalkylindoles recruit arrestin, framing biased agonism as a design principle.","evidence":"Adenylyl cyclase inhibition and BRET β-arrestin recruitment assays across a structurally diverse ligand panel","pmids":["27194477"],"confidence":"High","gaps":["Structural basis of bias not resolved in this study","Physiological consequence of bias in vivo not addressed"]},{"year":2018,"claim":"Showed CB2-CXCR4 heterodimerization suppresses chemokine-driven migration and invasion via inhibition of the Gα13/RhoA cytoskeletal axis.","evidence":"Co-IP, colocalization, migration/invasion/adhesion assays, and Gα13/RhoA Western blots","pmids":["29330286"],"confidence":"Medium","gaps":["Single lab","Direct interface and in vivo relevance limited"]},{"year":2019,"claim":"Provided the first atomic structure of CB2 (antagonist-bound crystal), revealing a distinct binding pose from CB1 and the molecular determinants of CB1/CB2 selectivity.","evidence":"2.8 Å X-ray crystallography with site-directed mutagenesis and molecular docking","pmids":["30639103"],"confidence":"High","gaps":["Antagonist-bound state only","Active-state and G-protein coupling not captured"]},{"year":2022,"claim":"Identified a non-canonical CB2 mechanism—direct JAK1 binding that suppresses STAT signaling—explaining cannabinoid impairment of tumor-specific T-cell function, and localized antinociceptive CB2 to peripheral sensory neurons.","evidence":"FLAG-Cnr2 knock-in mouse with FLAG pulldown of JAK1 and STAT assays; advillinCre;CB2f/f conditional knockout with neuropathic pain and morphine tolerance assays","pmids":["35383142","36417942"],"confidence":"High","gaps":["Whether JAK1 binding is G-protein-independent not fully resolved","Structural basis of CB2-JAK1 interaction undefined"]},{"year":2022,"claim":"Defined the CB2-Nurr1 axis in microglia, where β-arrestin2/ERK and PI3K/AKT/GSK-3β signaling drive Nurr1 nuclear translocation to inhibit phagocytosis.","evidence":"BV-2 and primary microglia with pathway inhibitors, Nurr1 overexpression, nuclear fractionation, and phagocytosis assays","pmids":["35132190"],"confidence":"Medium","gaps":["Single lab","In vivo microglial relevance not established"]},{"year":2023,"claim":"Cryo-EM of agonist-bound CB2 captured the active-state pocket and revealed a TM1-TM7 membrane channel through which lipophilic endocannabinoids access the binding site, unifying structural and pharmacological selectivity.","evidence":"Cryo-EM with multiple agonists, mutagenesis, binding kinetics, and in vivo nephropathy pharmacology","pmids":["36922494"],"confidence":"High","gaps":["Heteromer structures not resolved","Biased signaling structural states not separately captured"]},{"year":2024,"claim":"Demonstrated that engaging both protomers of the CB2 homodimer with a homobivalent ligand modulates dimerization dynamics to enhance both Gi signaling and arrestin recruitment, indicating dimer-level allosteric control.","evidence":"Computational docking, BRET homodimerization, Gi signaling, and β-arrestin recruitment assays","pmids":["39179054"],"confidence":"Medium","gaps":["Single lab","Structural confirmation of bivalent binding mode pending"]},{"year":null,"claim":"How CB2's many context-specific effector arms (Gi/cyclase, ERK, PI3K/Akt, AMPK/CREB, β-arrestin/Nurr1, JAK1/STAT) and its diverse heteromers are selected and integrated in a given cell type remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying model linking ligand bias to cell-type-specific effector choice","Structural basis of CB2 heteromers undefined","Endogenous regulation of CB2-JAK1 versus G-protein coupling unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,17,23]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,19,23]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,9,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,8,12,20]}],"complexes":["CB1-CB2 heteromer","CB2-GPR55 heteromer","HER2-CB2 heteromer","CB2-CXCR4 heterodimer"],"partners":["CNR1","GPR55","ERBB2","CXCR4","JAK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P34972","full_name":"Cannabinoid receptor 2","aliases":["CX5"],"length_aa":360,"mass_kda":39.7,"function":"Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis","subcellular_location":"Cell membrane; Cell projection, dendrite; Perikaryon","url":"https://www.uniprot.org/uniprotkb/P34972/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CNR2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CNR2","total_profiled":1310},"omim":[{"mim_id":"613599","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 12, LYSOPHOSPHOLIPASE; ABHD12","url":"https://www.omim.org/entry/613599"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"606928","title":"BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 3; BMND3","url":"https://www.omim.org/entry/606928"},{"mim_id":"606312","title":"PROTOCADHERIN-ALPHA 6; PCDHA6","url":"https://www.omim.org/entry/606312"},{"mim_id":"605051","title":"CANNABINOID RECEPTOR 2; CNR2","url":"https://www.omim.org/entry/605051"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":3.1},{"tissue":"lymphoid tissue","ntpm":8.4}],"url":"https://www.proteinatlas.org/search/CNR2"},"hgnc":{"alias_symbol":["CB2"],"prev_symbol":[]},"alphafold":{"accession":"P34972","domains":[{"cath_id":"1.20.1070.10","chopping":"21-169_178-223_234-315","consensus_level":"medium","plddt":92.7884,"start":21,"end":315}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P34972","model_url":"https://alphafold.ebi.ac.uk/files/AF-P34972-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P34972-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CNR2","jax_strain_url":"https://www.jax.org/strain/search?query=CNR2"},"sequence":{"accession":"P34972","fasta_url":"https://rest.uniprot.org/uniprotkb/P34972.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P34972/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P34972"}},"corpus_meta":[{"pmid":"9336020","id":"PMC_9336020","title":"Pharmacology of cannabinoid CB1 and CB2 receptors.","date":"1997","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/9336020","citation_count":1199,"is_preprint":false},{"pmid":"20590558","id":"PMC_20590558","title":"CB2: a cannabinoid receptor with an identity crisis.","date":"2010","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20590558","citation_count":501,"is_preprint":false},{"pmid":"27402121","id":"PMC_27402121","title":"The CB2 receptor and its role as a regulator of inflammation.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27402121","citation_count":452,"is_preprint":false},{"pmid":"16407142","id":"PMC_16407142","title":"Peripheral cannabinoid receptor, CB2, regulates bone mass.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16407142","citation_count":428,"is_preprint":false},{"pmid":"17105950","id":"PMC_17105950","title":"Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17105950","citation_count":425,"is_preprint":false},{"pmid":"18584858","id":"PMC_18584858","title":"Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.","date":"2008","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/18584858","citation_count":332,"is_preprint":false},{"pmid":"19152719","id":"PMC_19152719","title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.","date":"2009","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19152719","citation_count":328,"is_preprint":false},{"pmid":"30639103","id":"PMC_30639103","title":"Crystal Structure of the Human Cannabinoid Receptor CB2.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/30639103","citation_count":307,"is_preprint":false},{"pmid":"17141334","id":"PMC_17141334","title":"Cannabinoid CB2 receptor: a new target for controlling neural cell survival?","date":"2006","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17141334","citation_count":306,"is_preprint":false},{"pmid":"28826534","id":"PMC_28826534","title":"CB1 and CB2 Receptor Pharmacology.","date":"2017","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/28826534","citation_count":262,"is_preprint":false},{"pmid":"25106425","id":"PMC_25106425","title":"CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?","date":"2014","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25106425","citation_count":213,"is_preprint":false},{"pmid":"19496827","id":"PMC_19496827","title":"Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.","date":"2009","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/19496827","citation_count":208,"is_preprint":false},{"pmid":"22532560","id":"PMC_22532560","title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22532560","citation_count":192,"is_preprint":false},{"pmid":"28861504","id":"PMC_28861504","title":"Cannabinoid CB1 and CB2 Receptor Signaling and Bias.","date":"2017","source":"Cannabis and cannabinoid research","url":"https://pubmed.ncbi.nlm.nih.gov/28861504","citation_count":171,"is_preprint":false},{"pmid":"30611802","id":"PMC_30611802","title":"Progress in brain cannabinoid CB2 receptor research: From genes to behavior.","date":"2019","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30611802","citation_count":166,"is_preprint":false},{"pmid":"16356641","id":"PMC_16356641","title":"Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study.","date":"2005","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16356641","citation_count":166,"is_preprint":false},{"pmid":"19150370","id":"PMC_19150370","title":"Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.","date":"2008","source":"Brain research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19150370","citation_count":162,"is_preprint":false},{"pmid":"22763024","id":"PMC_22763024","title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients.","date":"2012","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22763024","citation_count":157,"is_preprint":false},{"pmid":"12084572","id":"PMC_12084572","title":"Cloning and molecular characterization of the rat CB2 cannabinoid receptor.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12084572","citation_count":149,"is_preprint":false},{"pmid":"21626285","id":"PMC_21626285","title":"Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.","date":"2011","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/21626285","citation_count":148,"is_preprint":false},{"pmid":"16563625","id":"PMC_16563625","title":"CB2 cannabinoid receptor mediation of antinociception.","date":"2006","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/16563625","citation_count":146,"is_preprint":false},{"pmid":"19931854","id":"PMC_19931854","title":"Brain cannabinoid CB2 receptor in schizophrenia.","date":"2009","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19931854","citation_count":144,"is_preprint":false},{"pmid":"21447538","id":"PMC_21447538","title":"CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.","date":"2011","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21447538","citation_count":141,"is_preprint":false},{"pmid":"9808554","id":"PMC_9808554","title":"Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9808554","citation_count":141,"is_preprint":false},{"pmid":"23414569","id":"PMC_23414569","title":"Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23414569","citation_count":135,"is_preprint":false},{"pmid":"33375006","id":"PMC_33375006","title":"CB2 Receptor in Microglia: The Guardian of Self-Control.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33375006","citation_count":120,"is_preprint":false},{"pmid":"26515747","id":"PMC_26515747","title":"Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26515747","citation_count":118,"is_preprint":false},{"pmid":"17328768","id":"PMC_17328768","title":"CB2 cannabinoid receptors promote mouse neural stem cell proliferation.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17328768","citation_count":116,"is_preprint":false},{"pmid":"10750830","id":"PMC_10750830","title":"Expression of CB2 cannabinoid receptor mRNA in adult rat retina.","date":"2000","source":"Visual neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10750830","citation_count":115,"is_preprint":false},{"pmid":"19541620","id":"PMC_19541620","title":"The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19541620","citation_count":114,"is_preprint":false},{"pmid":"23865723","id":"PMC_23865723","title":"Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23865723","citation_count":109,"is_preprint":false},{"pmid":"17430144","id":"PMC_17430144","title":"The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists.","date":"2007","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17430144","citation_count":109,"is_preprint":false},{"pmid":"25048571","id":"PMC_25048571","title":"Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.","date":"2014","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25048571","citation_count":107,"is_preprint":false},{"pmid":"19333940","id":"PMC_19333940","title":"The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19333940","citation_count":105,"is_preprint":false},{"pmid":"27303261","id":"PMC_27303261","title":"CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease.","date":"2016","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27303261","citation_count":103,"is_preprint":false},{"pmid":"25855725","id":"PMC_25855725","title":"Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.","date":"2015","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/25855725","citation_count":100,"is_preprint":false},{"pmid":"24942731","id":"PMC_24942731","title":"Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24942731","citation_count":99,"is_preprint":false},{"pmid":"17906679","id":"PMC_17906679","title":"Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17906679","citation_count":97,"is_preprint":false},{"pmid":"18291574","id":"PMC_18291574","title":"Role of CB2 receptors in neuroprotective effects of cannabinoids.","date":"2008","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18291574","citation_count":96,"is_preprint":false},{"pmid":"17952109","id":"PMC_17952109","title":"CB2 receptors as new therapeutic targets for liver diseases.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17952109","citation_count":91,"is_preprint":false},{"pmid":"24877594","id":"PMC_24877594","title":"What we know and do not know about the cannabinoid receptor 2 (CB2).","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24877594","citation_count":88,"is_preprint":false},{"pmid":"16026310","id":"PMC_16026310","title":"CB2 receptor ligands.","date":"2005","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16026310","citation_count":83,"is_preprint":false},{"pmid":"31368508","id":"PMC_31368508","title":"Cannabichromene is a cannabinoid CB2 receptor agonist.","date":"2019","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31368508","citation_count":83,"is_preprint":false},{"pmid":"39179054","id":"PMC_39179054","title":"Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/39179054","citation_count":78,"is_preprint":false},{"pmid":"27194477","id":"PMC_27194477","title":"Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.","date":"2016","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27194477","citation_count":78,"is_preprint":false},{"pmid":"31024316","id":"PMC_31024316","title":"Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31024316","citation_count":77,"is_preprint":false},{"pmid":"18537620","id":"PMC_18537620","title":"Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.","date":"2008","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18537620","citation_count":74,"is_preprint":false},{"pmid":"20166925","id":"PMC_20166925","title":"Cannabinoid CB(2) receptors in health and disease.","date":"2010","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20166925","citation_count":73,"is_preprint":false},{"pmid":"20621164","id":"PMC_20621164","title":"CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.","date":"2010","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20621164","citation_count":72,"is_preprint":false},{"pmid":"27713365","id":"PMC_27713365","title":"Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.","date":"2010","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/27713365","citation_count":71,"is_preprint":false},{"pmid":"23855434","id":"PMC_23855434","title":"Role of cannabinoid CB2 receptor in the reinforcing actions of ethanol.","date":"2013","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/23855434","citation_count":71,"is_preprint":false},{"pmid":"20803555","id":"PMC_20803555","title":"CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts.","date":"2011","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/20803555","citation_count":69,"is_preprint":false},{"pmid":"17311616","id":"PMC_17311616","title":"Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease.","date":"2007","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/17311616","citation_count":65,"is_preprint":false},{"pmid":"10903395","id":"PMC_10903395","title":"The search for selective ligands for the CB2 receptor.","date":"2000","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/10903395","citation_count":64,"is_preprint":false},{"pmid":"35383142","id":"PMC_35383142","title":"Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35383142","citation_count":62,"is_preprint":false},{"pmid":"27215781","id":"PMC_27215781","title":"Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.","date":"2016","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/27215781","citation_count":61,"is_preprint":false},{"pmid":"24836296","id":"PMC_24836296","title":"Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.","date":"2014","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24836296","citation_count":60,"is_preprint":false},{"pmid":"15892633","id":"PMC_15892633","title":"Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.","date":"2005","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15892633","citation_count":59,"is_preprint":false},{"pmid":"22197668","id":"PMC_22197668","title":"CB₂: therapeutic target-in-waiting.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22197668","citation_count":58,"is_preprint":false},{"pmid":"16981823","id":"PMC_16981823","title":"Targeting the CB2 receptor for immune modulation.","date":"2006","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/16981823","citation_count":58,"is_preprint":false},{"pmid":"36922494","id":"PMC_36922494","title":"Structural basis of selective cannabinoid CB2 receptor activation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36922494","citation_count":58,"is_preprint":false},{"pmid":"19480992","id":"PMC_19480992","title":"Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.","date":"2009","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/19480992","citation_count":56,"is_preprint":false},{"pmid":"35055161","id":"PMC_35055161","title":"New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35055161","citation_count":54,"is_preprint":false},{"pmid":"23951024","id":"PMC_23951024","title":"Cannabinoid receptor CB2 modulates axon guidance.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23951024","citation_count":54,"is_preprint":false},{"pmid":"26406232","id":"PMC_26406232","title":"Expression Analysis of CB2-GFP BAC Transgenic Mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26406232","citation_count":53,"is_preprint":false},{"pmid":"17982473","id":"PMC_17982473","title":"Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17982473","citation_count":53,"is_preprint":false},{"pmid":"18468662","id":"PMC_18468662","title":"Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder.","date":"2008","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/18468662","citation_count":53,"is_preprint":false},{"pmid":"22948261","id":"PMC_22948261","title":"CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence.","date":"2012","source":"European addiction research","url":"https://pubmed.ncbi.nlm.nih.gov/22948261","citation_count":47,"is_preprint":false},{"pmid":"37164044","id":"PMC_37164044","title":"CB2 receptor in the CNS: From immune and neuronal modulation to behavior.","date":"2023","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37164044","citation_count":46,"is_preprint":false},{"pmid":"35273503","id":"PMC_35273503","title":"Expression and Functions of the CB2 Receptor in Human Leukocytes.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35273503","citation_count":46,"is_preprint":false},{"pmid":"35906103","id":"PMC_35906103","title":"Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future.","date":"2022","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35906103","citation_count":46,"is_preprint":false},{"pmid":"25980325","id":"PMC_25980325","title":"A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10.","date":"2015","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25980325","citation_count":46,"is_preprint":false},{"pmid":"20549374","id":"PMC_20549374","title":"Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.","date":"2010","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20549374","citation_count":46,"is_preprint":false},{"pmid":"19086305","id":"PMC_19086305","title":"Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei.","date":"2008","source":"Acta oto-laryngologica","url":"https://pubmed.ncbi.nlm.nih.gov/19086305","citation_count":45,"is_preprint":false},{"pmid":"30055149","id":"PMC_30055149","title":"Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30055149","citation_count":44,"is_preprint":false},{"pmid":"29330286","id":"PMC_29330286","title":"Agonist-induced CXCR4 and CB2 Heterodimerization Inhibits Gα13/RhoA-mediated Migration.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/29330286","citation_count":44,"is_preprint":false},{"pmid":"21658778","id":"PMC_21658778","title":"Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor.","date":"2011","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/21658778","citation_count":43,"is_preprint":false},{"pmid":"21828121","id":"PMC_21828121","title":"CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura.","date":"2011","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/21828121","citation_count":43,"is_preprint":false},{"pmid":"31215752","id":"PMC_31215752","title":"Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.","date":"2019","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/31215752","citation_count":41,"is_preprint":false},{"pmid":"17828289","id":"PMC_17828289","title":"CB2 receptors in reproduction.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17828289","citation_count":40,"is_preprint":false},{"pmid":"39064959","id":"PMC_39064959","title":"The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update.","date":"2024","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/39064959","citation_count":39,"is_preprint":false},{"pmid":"28752643","id":"PMC_28752643","title":"Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28752643","citation_count":36,"is_preprint":false},{"pmid":"29066974","id":"PMC_29066974","title":"Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.","date":"2017","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29066974","citation_count":36,"is_preprint":false},{"pmid":"35453624","id":"PMC_35453624","title":"Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Celiac Disease.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35453624","citation_count":35,"is_preprint":false},{"pmid":"19565271","id":"PMC_19565271","title":"The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19565271","citation_count":34,"is_preprint":false},{"pmid":"31452735","id":"PMC_31452735","title":"HTR1D, TIMP1, SERPINE1, MMP3 and CNR2 affect the survival of patients with colon adenocarcinoma.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31452735","citation_count":32,"is_preprint":false},{"pmid":"27842450","id":"PMC_27842450","title":"The central cannabinoid receptor type-2 (CB2) and chronic pain.","date":"2016","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27842450","citation_count":32,"is_preprint":false},{"pmid":"31517528","id":"PMC_31517528","title":"Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.","date":"2019","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31517528","citation_count":31,"is_preprint":false},{"pmid":"36551756","id":"PMC_36551756","title":"Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36551756","citation_count":31,"is_preprint":false},{"pmid":"12460775","id":"PMC_12460775","title":"Expression of CB2 cannabinoid receptor in Pichia pastoris.","date":"2002","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/12460775","citation_count":31,"is_preprint":false},{"pmid":"35001054","id":"PMC_35001054","title":"A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.","date":"2022","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/35001054","citation_count":31,"is_preprint":false},{"pmid":"34001284","id":"PMC_34001284","title":"Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.","date":"2021","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/34001284","citation_count":30,"is_preprint":false},{"pmid":"16621595","id":"PMC_16621595","title":"Bacterial expression of functional, biotinylated peripheral cannabinoid receptor CB2.","date":"2006","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/16621595","citation_count":30,"is_preprint":false},{"pmid":"36417942","id":"PMC_36417942","title":"Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36417942","citation_count":30,"is_preprint":false},{"pmid":"35132190","id":"PMC_35132190","title":"CB2 receptor activation inhibits the phagocytic function of microglia through activating ERK/AKT-Nurr1 signal pathways.","date":"2022","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/35132190","citation_count":29,"is_preprint":false},{"pmid":"30063884","id":"PMC_30063884","title":"Pharmacological regulation of cannabinoid CB2 receptor modulates the reinforcing and motivational actions of ethanol.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30063884","citation_count":29,"is_preprint":false},{"pmid":"36768668","id":"PMC_36768668","title":"Microglial Cannabinoid CB2 Receptors in Pain Modulation.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36768668","citation_count":28,"is_preprint":false},{"pmid":"31725603","id":"PMC_31725603","title":"The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31725603","citation_count":27,"is_preprint":false},{"pmid":"35492718","id":"PMC_35492718","title":"Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders.","date":"2022","source":"Frontiers in psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/35492718","citation_count":27,"is_preprint":false},{"pmid":"22227125","id":"PMC_22227125","title":"Cannabinoid receptor CB2 protects against balloon-induced neointima formation.","date":"2012","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22227125","citation_count":27,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45476,"output_tokens":6368,"usd":0.115974,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15386,"output_tokens":5180,"usd":0.103215,"stage2_stop_reason":"end_turn"},"total_usd":0.219189,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CB2 (CNR2) is a G protein-coupled receptor that couples to Gi proteins; its effector systems include inhibition of adenylyl cyclase. CB2 receptors are present in peripheral tissues and immune system.\",\n      \"method\": \"Pharmacological characterization, radioligand binding, effector assays\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — foundational pharmacological characterization replicated across multiple labs over decades\",\n      \"pmids\": [\"9336020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CB2 receptor expression is downregulated during B-cell differentiation (lowest in germinal center centroblasts), and CB2 receptor activation by cannabinoid agonist CP55,940 enhanced CD40-mediated B-cell proliferation, an effect blocked by CB2 antagonist SR 144528 but not CB1 antagonist SR 141716, demonstrating functional CB2 signaling in B-cell differentiation.\",\n      \"method\": \"Immunopurified anti-CB2 antibodies, dual-color confocal microscopy, flow cytometry, proliferation assays with selective antagonists\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (immunostaining, mRNA, protein, functional assay with receptor-selective pharmacology)\",\n      \"pmids\": [\"9808554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Rat CB2 (rCB2) activates mitogen-activated protein kinase (MAPK/ERK) when stably expressed in CHO cells, establishing a direct signaling output of CB2 receptor activation.\",\n      \"method\": \"Stable expression in CHO cells, MAPK activation assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, single method (MAPK assay in heterologous expression system)\",\n      \"pmids\": [\"12084572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Functional, epitope-tagged CB2 receptor was expressed in Pichia pastoris with pharmacological binding profile similar to mammalian-expressed receptor, and purified receptor was characterized by MALDI/TOF and ESI mass spectrometry.\",\n      \"method\": \"Heterologous expression in P. pastoris, radioligand binding, metal chelating chromatography, MALDI/TOF and ESI mass spectrometry\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — successful purification and functional validation but single lab, expression system study\",\n      \"pmids\": [\"12460775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB2-deficient mice show accelerated age-related trabecular bone loss with increased osteoclast numbers and decreased osteoblast precursors; CB2 is expressed in osteoblasts, osteocytes, and osteoclasts. A CB2-specific agonist enhances osteoblast number/activity and restrains osteoclastogenesis by inhibiting osteoclast precursor proliferation and RANKL expression in bone marrow-derived osteoblasts/stromal cells, and attenuates ovariectomy-induced bone loss.\",\n      \"method\": \"CB2 knockout mice, histomorphometry, pharmacological agonist treatment, ovariectomy model, bone cell culture assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout plus pharmacological rescue with multiple orthogonal readouts across multiple models\",\n      \"pmids\": [\"16407142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB2 receptor activation by AM1241 produces antinociception in wild-type mice but has no effect in CB2 knockout mice, demonstrating that antinociceptive effects of AM1241 are mediated specifically through CB2 receptors in vivo.\",\n      \"method\": \"CB2 knockout mice vs. wild-type, thermal nociception assay, pharmacological challenge\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with pharmacological validation, replicated with multiple agonists\",\n      \"pmids\": [\"16563625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CB2 receptor activation in neural stem/precursor cells (neurospheres) stimulates proliferation via a phosphoinositide-3 kinase (PI3K)/Akt signaling pathway; selective CB2 agonist JWH-056 stimulates neurosphere formation, and CB2 antagonist SR-144528 blocks basal proliferation, indicating endogenous cannabinoid tone through CB2.\",\n      \"method\": \"Neurosphere cultures, BrdU incorporation, pharmacological agonists/antagonists, PI3K/Akt inhibitor (BML-257)\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective pharmacology with PI3K/Akt pathway inhibitor, two orthogonal readouts (BrdU and neurosphere formation)\",\n      \"pmids\": [\"17328768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB2 receptor activation by selective agonist JWH133 induced ERK1/2 MAPK phosphorylation in spermatogonia and promoted their progression toward meiosis, increasing cells positive for meiotic marker SCP3 and early meiotic prophase gene expression; endogenous 2-AG (higher in mitotic germ cells) is the likely endocannabinoid signal acting through CB2 during spermatogenesis.\",\n      \"method\": \"Purified germ cell fractions, primary spermatogonia cultures, selective CB2 agonist, Western blot (ERK phosphorylation), immunostaining for SCP3, RT-PCR for meiotic genes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods in primary cells with specific pharmacological tools and functional meiosis readout\",\n      \"pmids\": [\"19541620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB2 limits leukocyte infiltration and tissue fibrosis in experimental dermal fibrosis; the fibrosis-suppressing effect is mediated by leukocyte-expressed CB2, as shown by bone marrow transplantation: CB2-/- bone marrow transplanted into wild-type mice recapitulated increased fibrosis, while wild-type marrow into CB2-/- mice rescued the phenotype.\",\n      \"method\": \"CB2 knockout mice, bleomycin-induced fibrosis model, pharmacological agonist/antagonist treatment, bone marrow transplantation, histology\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout plus bone marrow transplantation epistasis plus pharmacological rescue, multiple orthogonal approaches\",\n      \"pmids\": [\"19333940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB2 receptor signals through a Gi protein-cyclin D1 mitogenic axis in osteoblasts: CB2 activation stimulates ERK1/2 phosphorylation, de novo synthesis of MAPKAPK2, CREB transcriptional activation, and cyclin D1 mRNA expression; these effects are blocked by pertussis toxin (Gi inhibitor), MEK-ERK1/2 inhibitors, and Mapkapk2 siRNA.\",\n      \"method\": \"Osteoblast cultures (MC3T3 E1 and primary calvarial), selective CB2 agonists, Western blot, RT-PCR, CREB reporter assay, Mapkapk2 siRNA knockdown, pertussis toxin treatment\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including siRNA knockdown, pharmacological inhibitors at multiple pathway nodes, and Gi pathway confirmation with pertussis toxin\",\n      \"pmids\": [\"20803555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CB2 and CB1 receptors form functional heteromers in transfected neuronal cells and in rat brain (pineal gland, nucleus accumbens, globus pallidus). Within CB1-CB2 heteromers, co-activation produces negative cross-talk in Akt phosphorylation and neurite outgrowth. CB1 antagonists block CB2 agonist effects and vice versa (bidirectional cross-antagonism), a property unique to the heteromeric complex.\",\n      \"method\": \"BRET, FRET, co-immunoprecipitation in transfected cells and rat brain tissue, Akt phosphorylation assay, neurite outgrowth assay, pharmacological cross-antagonism\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — biophysical (BRET/FRET) plus biochemical (Co-IP) plus functional assays in both heterologous system and native brain tissue\",\n      \"pmids\": [\"22532560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB2 receptor activation by trans-caryophyllene (TC) reduced ischemic neuronal injury through AMPK/CREB signaling: TC enhanced phosphorylation of AMPK and CREB and increased BDNF expression; selective AMPK and CREB inhibitors abolished TC neuroprotection. TC failed to alter Akt or ERK activity (two canonical CB2R pathways). Effects were reversed by CB2 antagonist AM630 but not CB1 antagonist AM251.\",\n      \"method\": \"Rat cortical neuron/glia OGD/R model, CB2 knockout validation with AM630/AM251, Western blot, selective kinase inhibitors, in vivo rat ischemia model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple pathway inhibitors, receptor-selective pharmacology, in vitro and in vivo models, orthogonal biochemical readouts\",\n      \"pmids\": [\"23414569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB2 receptor activation by selective agonist O-1966 decreased nuclear NF-κB and NFAT levels in wild-type T-cells but not in CB2 knockout T-cells, and increased IL-10 production and regulatory T-cell (Treg) percentage in mixed lymphocyte reactions; increased IL-10 partially mediated the immunosuppressive effects.\",\n      \"method\": \"CB2 knockout mouse T-cells, mixed lymphocyte reaction, nuclear transcription factor assays, PCR T-cell activation array, IL-10 ELISA, anti-IL-10 neutralization\",\n      \"journal\": \"Journal of neuroimmune pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout controls plus multiple pathway readouts (NF-κB, NFAT, IL-10, Tregs) and neutralization experiment\",\n      \"pmids\": [\"25980325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB2 receptor modulates axon guidance in the retino-thalamic pathway in a PKA-dependent manner requiring the netrin-1 receptor DCC (Deleted in Colorectal Cancer); CB2R activation induced growth cone morphological changes, and cnr2-/- mice showed abnormal eye-specific segregation of retinal projections in the dLGN.\",\n      \"method\": \"cnr2 knockout mice, in vitro axon guidance assays, PKA inhibitor experiments, in vivo retino-thalamic tracing\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with specific phenotypic readout plus pharmacological PKA pathway dissection and in vivo circuit analysis\",\n      \"pmids\": [\"23951024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPR55 and CB2 receptors form heteromers in HEK293 cells (confirmed by co-immunoprecipitation and BRET); heteromerization selectively modulates signaling: GPR55-mediated transcription factor activation (NFAT, NF-κB, CRE) was reduced, while ERK1/2-MAPK activation was potentiated in the presence of CB2; CB2 signaling was also modified by co-expression with GPR55.\",\n      \"method\": \"Co-immunoprecipitation, BRET, label-free assays (Epic DMR and CellKey impedance), ERK1/2 phosphorylation assay, gene reporter assays\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus BRET plus multiple functional readouts, orthogonal methods\",\n      \"pmids\": [\"25048571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CB2 and GPR55 form heteromers in cancer cells with unique signaling properties; these heteromeric complexes modulate the antitumoral activity of cannabinoids in vivo.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, signaling assays, in vivo tumor model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and PLA plus in vivo functional data, single lab\",\n      \"pmids\": [\"24942731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HER2 upregulates CB2 expression by activating transcription factor ELK1 via the ERK cascade; increased CB2 expression activates HER2 pro-oncogenic signaling at the level of tyrosine kinase c-SRC; HER2 and CB2 form heteromers in cancer cells.\",\n      \"method\": \"siRNA/shRNA knockdown, overexpression plasmids, co-immunoprecipitation, proximity ligation assay, colocalization, MMTV-neu transgenic mice with CB2 knockout, biochemical signaling assays\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, PLA, genetic knockdown/KO, mouse model) demonstrating bidirectional HER2-CB2 interaction and signaling\",\n      \"pmids\": [\"25855725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CB2 receptor ligands display strong and varied functional selectivity: classic cannabinoids (e.g., JWH133) are highly efficacious for Gi-mediated adenylyl cyclase inhibition but fail to recruit arrestins (G-protein biased); endocannabinoids are also G-protein biased; aminoalkylindoles (e.g., WIN55212-2, UR144) show arrestin recruitment with varying cyclase efficacy; SR144258 is inverse agonist at both pathways; AM630 and JTE907 are inverse agonists at cyclase but low-efficacy agonists for arrestin recruitment.\",\n      \"method\": \"Adenylyl cyclase inhibition assay, β-arrestin recruitment assay (BRET-based), diverse CB2 ligand panel\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic screen with two orthogonal assays across a large structurally diverse ligand panel\",\n      \"pmids\": [\"27194477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCR4 and CB2 form heterodimers upon simultaneous agonist stimulation; this heterodimeric association inhibits CXCR4-mediated cell migration, invasion, and adhesion through inhibition of the Gα13/RhoA signaling axis, decreasing protein expression of Gα13 and RhoA, abrogating RhoA-mediated cytoskeletal rearrangement, and reducing integrin α5 (ITGA5) expression.\",\n      \"method\": \"Co-immunoprecipitation, confocal colocalization, migration/invasion/adhesion assays, Western blot for Gα13/RhoA, cytoskeletal rearrangement imaging\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus multiple functional readouts with pathway mechanistic dissection, single lab\",\n      \"pmids\": [\"29330286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of human CB2 receptor in complex with antagonist AM10257 was solved at 2.8 Å resolution. The structure revealed a distinctly different binding pose compared with CB1, but the extracellular portion shares conformational similarity with agonist-bound CB1. Mutagenesis and molecular docking identified molecular determinants of CB2/CB1 selectivity and the CB2 activation mechanism.\",\n      \"method\": \"X-ray crystallography (2.8 Å), site-directed mutagenesis, molecular docking, pharmacological assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis plus functional validation in one study\",\n      \"pmids\": [\"30639103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CNR2 (CB2 receptor) binds to JAK1 in T cells and inhibits downstream STAT signaling; this was demonstrated using a knock-in mouse model expressing FLAG-tagged Cnr2, with cannabinoids (THC and AEA) impairing tumor-specific T-cell function through CNR2-mediated JAK1/STAT inhibition.\",\n      \"method\": \"FLAG-Cnr2 knock-in mouse model, co-immunoprecipitation (FLAG pulldown for JAK1 binding), T-cell functional assays, STAT phosphorylation assays, in vivo tumor models\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse model with tagged endogenous receptor plus Co-IP demonstrating JAK1 binding plus functional pathway readouts\",\n      \"pmids\": [\"35383142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CB2 receptors localized to peripheral sensory neurons (advillin-expressing) are necessary for both CB2 agonist (AM1710 and LY2828360) antinociceptive efficacy and sparing of morphine tolerance in a mouse model of antiretroviral toxic neuropathy; advillinCre/+;CB2f/f conditional knockout mice lacked these CB2 agonist effects.\",\n      \"method\": \"Conditional knockout (advillinCre/+;CB2f/f), global CB2 KO, neuropathic pain behavioral assays, morphine tolerance assay, cytokine mRNA measurement\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockout with multiple behavioral and molecular readouts, two structurally distinct CB2 agonists tested\",\n      \"pmids\": [\"36417942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CB2 receptor activation inhibits microglial phagocytic function through β-arrestin2/ERK1/2 and PI3K/AKT/GSK-3β signaling pathways leading to nuclear translocation of Nurr1; positive feedback exists between CB2 receptor and Nurr1 expression; ERK1/2 plays a more dominant role than AKT in the CB2-Nurr1 axis.\",\n      \"method\": \"BV-2 cells and primary microglia, CB2 agonists (JWH015, 2-AG), selective pathway inhibitors (U0126, LY294002), Nurr1 overexpression, nuclear fractionation Western blot, phagocytosis assay\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological pathway inhibitors and functional phagocytosis readout, single lab\",\n      \"pmids\": [\"35132190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of CB2 receptor bound to multiple agonists (LEI-102, APD371, HU308, CP55,940) identified key residues for CB2 activation by site-directed mutagenesis and binding kinetics; highly lipophilic agonists (HU308 and endocannabinoids) access the binding pocket through a membrane channel formed by TM1-TM7, while more polar agonists enter directly.\",\n      \"method\": \"Cryo-EM structural determination, site-directed mutagenesis, radioligand binding kinetics, molecular docking, in vivo pharmacology (oral efficacy in nephropathy model)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure plus mutagenesis plus binding kinetics plus in vivo validation, multiple ligands compared\",\n      \"pmids\": [\"36922494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A homobivalent ligand simultaneously binding both protomers of the CB2 receptor homodimer (one pharmacophore at orthosteric site, one at a TM1-TM7 membrane-oriented pocket of partner protomer) modulates CB2R homodimerization dynamics, resulting in increased potency for Gi-mediated signaling and enhanced β-arrestin recruitment.\",\n      \"method\": \"Computational docking, BRET for homodimerization, Gi signaling assays, β-arrestin recruitment assays, bivalent ligand pharmacology\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BRET for dimerization plus functional assays, computational modeling supporting binding mode, single lab\",\n      \"pmids\": [\"39179054\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CNR2/CB2 is a Gi/o protein-coupled receptor predominantly expressed in immune cells and peripheral tissues (with lower-level neuronal/glial expression), whose activation inhibits adenylyl cyclase, activates ERK1/2 MAPK through Gi, and can signal through AMPK/CREB and PI3K/Akt pathways depending on cell context; structurally, crystal and cryo-EM structures have defined its orthosteric binding pocket, a lipophilic TM1-TM7 membrane access channel for endocannabinoids, and the molecular basis of CB1/CB2 selectivity; CB2 forms functionally distinct heteromers with CB1, GPR55, HER2, and CXCR4 that alter downstream signaling; it directly binds JAK1 to suppress STAT signaling in T cells; functionally, CB2 regulates osteoblast/osteoclast activity via a Gi-cyclin D1 mitogenic axis, suppresses leukocyte infiltration and fibrosis, promotes neural stem cell proliferation, modulates axon guidance through PKA-DCC, inhibits microglial phagocytosis via β-arrestin2/ERK-Nurr1, and peripheral sensory neuron CB2 specifically mediates antinociception and morphine tolerance-sparing effects.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CNR2/CB2 is a Gi/o-coupled cannabinoid receptor that transduces endocannabinoid signals predominantly in immune and peripheral tissues, classically inhibiting adenylyl cyclase and activating ERK1/2 MAPK [#0, #2]. Through its Gi output CB2 drives a mitogenic axis in osteoblasts coupling ERK1/2, MAPKAPK2, and CREB to cyclin D1 transcription, and genetically governs bone homeostasis by promoting osteoblast activity while restraining osteoclastogenesis [#4, #9]. Depending on cell context CB2 signals through additional effector arms—PI3K/Akt to drive neural stem cell and germ cell proliferation [#6, #7], AMPK/CREB/BDNF for neuroprotection [#11], and β-arrestin2/ERK-PI3K/AKT/GSK-3β converging on Nurr1 to suppress microglial phagocytosis [#22]. CB2 ligands are strongly functionally selective, with classic cannabinoids and endocannabinoids biased toward G-protein signaling over arrestin recruitment [#17]. In immune cells CB2 is broadly anti-inflammatory: it enhances CD40-driven B-cell proliferation [#1], dampens NF-κB/NFAT and promotes IL-10/Treg responses in T cells [#12], limits leukocyte-driven tissue fibrosis [#8], and directly binds JAK1 to inhibit STAT signaling and suppress tumor-specific T-cell function [#20]. CB2 forms functionally distinct heteromers with CB1, GPR55, HER2, and CXCR4 that reshape downstream signaling, including cross-antagonism with CB1, modulation of GPR55 transcription-factor output, HER2 pro-oncogenic feedback, and inhibition of CXCR4-driven migration via Gα13/RhoA [#10, #14, #16, #18]. In the nervous system CB2 also modulates axon guidance through a PKA-DCC mechanism [#13], and peripheral sensory-neuron CB2 specifically mediates antinociception and morphine-tolerance sparing [#5, #21]. Crystal and cryo-EM structures define the CB2 orthosteric pocket, the molecular basis of CB1/CB2 selectivity, and a lipophilic TM1-TM7 membrane-access channel used by endocannabinoids [#19, #23].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the foundational identity of CB2 as a Gi-coupled receptor with a peripheral/immune distribution and adenylyl cyclase inhibition as a core effector, defining the receptor's basic signaling logic.\",\n      \"evidence\": \"Pharmacological characterization, radioligand binding, and effector assays\",\n      \"pmids\": [\"9336020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define downstream kinase cascades\", \"Did not resolve cell-type-specific functions\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated CB2 is functionally engaged in immune cell biology, showing receptor-selective enhancement of CD40-mediated B-cell proliferation during differentiation.\",\n      \"evidence\": \"Anti-CB2 immunostaining, flow cytometry, and proliferation assays with CB2- vs CB1-selective antagonists\",\n      \"pmids\": [\"9808554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway linking CB2 to proliferation not defined\", \"In vivo relevance to humoral immunity untested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified MAPK/ERK activation as a direct CB2 signaling output, extending the effector repertoire beyond cyclase inhibition.\",\n      \"evidence\": \"Stable rat CB2 expression in CHO cells with MAPK activation assay\",\n      \"pmids\": [\"12084572\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single heterologous system\", \"G-protein dependence not dissected\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic and pharmacological evidence placed CB2 at the center of bone homeostasis and in vivo antinociception, two of its defining physiological roles.\",\n      \"evidence\": \"CB2 knockout mice with histomorphometry, ovariectomy and bone cell models, and thermal nociception with CB2-selective agonist AM1241\",\n      \"pmids\": [\"16407142\", \"16563625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular mechanism in bone cells not yet resolved\", \"Cell type mediating antinociception not localized\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linked CB2 to proliferative control in neural and germ-cell lineages, identifying PI3K/Akt and ERK1/2 as proliferative effector arms under endogenous endocannabinoid tone.\",\n      \"evidence\": \"Neurosphere cultures with PI3K/Akt inhibitor and selective pharmacology; primary spermatogonia with ERK phosphorylation and meiotic markers (2009)\",\n      \"pmids\": [\"17328768\", \"19541620\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reliance on pharmacology rather than genetic deletion in these systems\", \"Endocannabinoid identity inferred\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Bone marrow transplantation epistasis established that leukocyte-expressed CB2 is the cell-autonomous source restraining tissue fibrosis, distinguishing immune from parenchymal CB2.\",\n      \"evidence\": \"CB2 knockout, bleomycin fibrosis model, and reciprocal bone marrow transplantation\",\n      \"pmids\": [\"19333940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific leukocyte subset not identified\", \"Downstream anti-fibrotic mediators undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved the CB2 mitogenic mechanism in osteoblasts as a Gi-ERK1/2-MAPKAPK2-CREB-cyclin D1 axis, providing a defined pathway for CB2-driven proliferation.\",\n      \"evidence\": \"Osteoblast cultures with pertussis toxin, MEK inhibitors, Mapkapk2 siRNA, and CREB reporter assays\",\n      \"pmids\": [\"20803555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability of this axis to other proliferative tissues untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated that CB2 oligomerizes with other receptors to generate novel signaling units, beginning with CB1-CB2 heteromers showing bidirectional cross-antagonism and negative Akt cross-talk.\",\n      \"evidence\": \"BRET, FRET, Co-IP in transfected cells and rat brain with Akt and neurite outgrowth readouts\",\n      \"pmids\": [\"22532560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural interface unresolved\", \"Physiological consequence in native circuits limited\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Expanded CB2's context-dependent signaling and partner network: AMPK/CREB neuroprotection, T-cell immunosuppression via NF-κB/NFAT and IL-10/Tregs, GPR55 heteromer signaling rewiring, and PKA-DCC-dependent axon guidance.\",\n      \"evidence\": \"OGD/R neuron models, CB2-KO T cells in mixed lymphocyte reactions, Co-IP/BRET for GPR55 heteromers, and cnr2-KO retino-thalamic tracing\",\n      \"pmids\": [\"23414569\", \"25980325\", \"25048571\", \"23951024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which effector arm dominates is cell-context specific and not unified\", \"Heteromer interfaces not structurally defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established bidirectional HER2-CB2 cross-regulation in cancer, where HER2 induces CB2 via ERK-ELK1 and CB2 in turn amplifies HER2 oncogenic signaling through c-SRC.\",\n      \"evidence\": \"siRNA/shRNA, overexpression, Co-IP, PLA, and MMTV-neu;CB2-KO mouse model\",\n      \"pmids\": [\"25855725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heteromer structural basis undefined\", \"Therapeutic exploitability untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Systematically defined CB2 ligand functional selectivity, showing classic cannabinoids and endocannabinoids are G-protein biased while aminoalkylindoles recruit arrestin, framing biased agonism as a design principle.\",\n      \"evidence\": \"Adenylyl cyclase inhibition and BRET β-arrestin recruitment assays across a structurally diverse ligand panel\",\n      \"pmids\": [\"27194477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of bias not resolved in this study\", \"Physiological consequence of bias in vivo not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed CB2-CXCR4 heterodimerization suppresses chemokine-driven migration and invasion via inhibition of the Gα13/RhoA cytoskeletal axis.\",\n      \"evidence\": \"Co-IP, colocalization, migration/invasion/adhesion assays, and Gα13/RhoA Western blots\",\n      \"pmids\": [\"29330286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct interface and in vivo relevance limited\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the first atomic structure of CB2 (antagonist-bound crystal), revealing a distinct binding pose from CB1 and the molecular determinants of CB1/CB2 selectivity.\",\n      \"evidence\": \"2.8 Å X-ray crystallography with site-directed mutagenesis and molecular docking\",\n      \"pmids\": [\"30639103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Antagonist-bound state only\", \"Active-state and G-protein coupling not captured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified a non-canonical CB2 mechanism—direct JAK1 binding that suppresses STAT signaling—explaining cannabinoid impairment of tumor-specific T-cell function, and localized antinociceptive CB2 to peripheral sensory neurons.\",\n      \"evidence\": \"FLAG-Cnr2 knock-in mouse with FLAG pulldown of JAK1 and STAT assays; advillinCre;CB2f/f conditional knockout with neuropathic pain and morphine tolerance assays\",\n      \"pmids\": [\"35383142\", \"36417942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether JAK1 binding is G-protein-independent not fully resolved\", \"Structural basis of CB2-JAK1 interaction undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the CB2-Nurr1 axis in microglia, where β-arrestin2/ERK and PI3K/AKT/GSK-3β signaling drive Nurr1 nuclear translocation to inhibit phagocytosis.\",\n      \"evidence\": \"BV-2 and primary microglia with pathway inhibitors, Nurr1 overexpression, nuclear fractionation, and phagocytosis assays\",\n      \"pmids\": [\"35132190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo microglial relevance not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM of agonist-bound CB2 captured the active-state pocket and revealed a TM1-TM7 membrane channel through which lipophilic endocannabinoids access the binding site, unifying structural and pharmacological selectivity.\",\n      \"evidence\": \"Cryo-EM with multiple agonists, mutagenesis, binding kinetics, and in vivo nephropathy pharmacology\",\n      \"pmids\": [\"36922494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heteromer structures not resolved\", \"Biased signaling structural states not separately captured\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that engaging both protomers of the CB2 homodimer with a homobivalent ligand modulates dimerization dynamics to enhance both Gi signaling and arrestin recruitment, indicating dimer-level allosteric control.\",\n      \"evidence\": \"Computational docking, BRET homodimerization, Gi signaling, and β-arrestin recruitment assays\",\n      \"pmids\": [\"39179054\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Structural confirmation of bivalent binding mode pending\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CB2's many context-specific effector arms (Gi/cyclase, ERK, PI3K/Akt, AMPK/CREB, β-arrestin/Nurr1, JAK1/STAT) and its diverse heteromers are selected and integrated in a given cell type remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying model linking ligand bias to cell-type-specific effector choice\", \"Structural basis of CB2 heteromers undefined\", \"Endogenous regulation of CB2-JAK1 versus G-protein coupling unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 17, 23]},\n      {\"term_id\": \"GO:0004930\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 19, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 9, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 8, 12, 20]}\n    ],\n    \"complexes\": [\n      \"CB1-CB2 heteromer\",\n      \"CB2-GPR55 heteromer\",\n      \"HER2-CB2 heteromer\",\n      \"CB2-CXCR4 heterodimer\"\n    ],\n    \"partners\": [\n      \"CNR1\",\n      \"GPR55\",\n      \"ERBB2\",\n      \"CXCR4\",\n      \"JAK1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}